China Resources Pharmaceutical Group (HKSE:03320) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China Resources Pharmaceutical Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.07.

China Resources Pharmaceutical Group's long-term debt to total assets ratio increased from Dec. 2022 (0.05) to Dec. 2023 (0.07). It may suggest that China Resources Pharmaceutical Group is progressively becoming more dependent on debt to grow their business.

China Resources Pharmaceutical Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for China Resources Pharmaceutical Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group LT-Debt-to-Total-Asset Chart

China Resources Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.02

0.03

0.05

0.07

China Resources Pharmaceutical Group Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.05	0.05	0.05	0.07

China Resources Pharmaceutical Group LT-Debt-to-Total-Asset Calculation

China Resources Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	17431.961	/	269912.139
	=	0.06

China Resources Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	17431.961	/	269912.139
	=	0.06

China Resources Pharmaceutical Group (HKSE:03320) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China Resources Pharmaceutical Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group (HKSE:03320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

Executives

Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si

2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines